[Juvenile verrucae planae: treatment with imiquimod 5% cream]. 2007

M Mühlstädt, and K Kerschenlohr, and E-M Scharrer, and W Pfützner, and H C Korting
Klinik und Poliklinik für Dermatologie und Allergologie, Klinikum der Universität München, Frauenlobstrasse 9-11, 80337, München, Germany. mmuehlst@med.uni-muenchen.de

A 6 year old girl presented with flat-topped, skin-colored, partly grouped papules with slightly roughened surface on the left side of the forehead and around the left orbit. In an off-label use imiquimod 5% cream was applied twice a week before bedtime and was rinsed off in the morning. After four weeks of treatment the lesions had vanished completely. We suggest imiquimod 5% cream as a treatment option for juvenile plane warts even in children and in the face.

UI MeSH Term Description Entries
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003879 Dermatologic Agents Drugs used to treat or prevent skin disorders or for the routine care of skin. Agent, Dermatologic,Agent, Dermatological,Agents, Dermatologic,Dermatologic Agent,Dermatological Agents,Agents, Dermatological,Dermatological Agent
D005148 Facial Dermatoses Skin diseases involving the FACE. Favre-Racouchot Syndrome,Nodular Elastoidosis,Facial Dermatosis,Nodular Elastosis,Dermatoses, Facial,Dermatosis, Facial,Elastoidoses, Nodular,Elastoidosis, Nodular,Elastoses, Nodular,Elastosis, Nodular,Favre Racouchot Syndrome,Nodular Elastoidoses,Nodular Elastoses,Syndrome, Favre-Racouchot
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077271 Imiquimod A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS. 1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine,Aldara,R 837,R-837,S 26308,S-26308,Zyclara,R837
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000634 Aminoquinolines Quinolines substituted in any position by one or more amino groups.
D014860 Warts Benign epidermal proliferations or tumors; some are viral in origin. Verruca,Verrucas,Wart

Related Publications

M Mühlstädt, and K Kerschenlohr, and E-M Scharrer, and W Pfützner, and H C Korting
January 2011, Acta dermatovenerologica Croatica : ADC,
M Mühlstädt, and K Kerschenlohr, and E-M Scharrer, and W Pfützner, and H C Korting
May 2001, Archives of dermatology,
M Mühlstädt, and K Kerschenlohr, and E-M Scharrer, and W Pfützner, and H C Korting
April 1948, Nordisk medicin,
M Mühlstädt, and K Kerschenlohr, and E-M Scharrer, and W Pfützner, and H C Korting
May 2003, Journal of the European Academy of Dermatology and Venereology : JEADV,
M Mühlstädt, and K Kerschenlohr, and E-M Scharrer, and W Pfützner, and H C Korting
April 1948, Nordisk medicin,
M Mühlstädt, and K Kerschenlohr, and E-M Scharrer, and W Pfützner, and H C Korting
January 1951, A.M.A. archives of dermatology and syphilology,
M Mühlstädt, and K Kerschenlohr, and E-M Scharrer, and W Pfützner, and H C Korting
September 1971, Archives of dermatology,
M Mühlstädt, and K Kerschenlohr, and E-M Scharrer, and W Pfützner, and H C Korting
July 1980, Cutis,
M Mühlstädt, and K Kerschenlohr, and E-M Scharrer, and W Pfützner, and H C Korting
October 2007, Journal of drugs in dermatology : JDD,
M Mühlstädt, and K Kerschenlohr, and E-M Scharrer, and W Pfützner, and H C Korting
November 2006, Clinical and experimental dermatology,
Copied contents to your clipboard!